[18F]NAV4694

Phase 3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Dementia

Conditions

Dementia, Alzheimer's Disease

Trial Timeline

Jun 1, 2013 → Sep 1, 2018

NCT ID

NCT01886820

About [18F]NAV4694

[18F]NAV4694 is a phase 3 stage product being developed by Navidea Biopharmaceuticals for Dementia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01886820. Target conditions include Dementia, Alzheimer's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Dementia were approved

Approved (9) Terminated (1) Active (10)

✅E2020 + PlaceboEisaiApproved

✅donepezil hydrochloride (Aricept)EisaiApproved

✅MecobalaminEisaiApproved

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅Risperdal,reminylJohnson & JohnsonApproved

✅ENA713NovartisApproved

✅Rivastigmine Patch 9.5 cm2NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01886820	Phase 3	UNKNOWN	Jun 1, 2013	Sep 1, 2018	Dementia
NCT01812213	Phase 2	Terminated	Mar 1, 2013	Nov 2, 2017	Mild Cognitive Impairment
NCT01680588	Phase 2	UNKNOWN	Aug 1, 2012	Dec 1, 2018	Alzheimer Disease

Competing Products

20 competing products in Dementia

See all competitors

Product	Company	Stage	Hype Score
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
ARICEPT	Eisai	Phase 3	40
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
Mecobalamin	Eisai	Approved	43
E2020 + Placebo	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43